Kantonsspital St.Gallen
login

Bayer 20324

abstract TRK fusion cancer is rare but presents as a variety of solid
tumors. Larotrectinib is a highly selective TRK inhibitor
that, in a pooled analysis of patients in phase 1/2 clinical
trials, demonstrated an effective and sustained response in
the majority of patients with TRK fusion cancer.
Because of the limited number of patients treated with
larotrectinib, information relating to its safety profile in a
broader population and over extended time periods is
lacking. Therefore, there is a need for data in a larger patient population, and for real-world data on larotrectinib
treatment.
This study will describe the safety and effectiveness of
larotrectinib under real-world treatment conditions and
provide information about the management of patients with locally advanced or metastatic TRK fusion cancer in
standard clinical practice.
   
type of project clinical studies
status scheduled
start of project 2021
end of project 2021
study design -
responsible person Dr. med. Barbara Bleisch